ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended			0 Months Ended
	Mar. 31, 2015 item	Mar. 31, 2014	Dec. 31, 2014	Oct. 18, 2013
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of product candidates under clinical development	1
Summary Of Significant Accounting Policies
Outstanding balance of the liability recognized in Non-cash royalty revenue		$ 42,784,000
Cash discount (as a percent)	2.00%
Discount reimbursement period after filling of prescription subject to discount	1 month
Minimum
Summary Of Significant Accounting Policies
Discount taken off period after the quarter in which product shipped to the customer	1 month
Period after the quarter in which prescription is filled for paying rebate	2 months
Minimum | Managed Care Rebates
Summary Of Significant Accounting Policies
Period after the quarter in which prescription is filled for rebate	1 month
Minimum | Medicare Part D Coverage Gap Rebates
Summary Of Significant Accounting Policies
Period after the quarter in which prescription is filled for rebate	2 months
Maximum
Summary Of Significant Accounting Policies
Product return period prior to expiration	6 months
Period after expiration for accepting unsalable product	12 months
Discount taken off period after the quarter in which product shipped to the customer	2 months
Period after the quarter in which prescription is filled for paying rebate	3 months
Maximum | Managed Care Rebates
Summary Of Significant Accounting Policies
Period after the quarter in which prescription is filled for rebate	3 months
Maximum | Medicare Part D Coverage Gap Rebates
Summary Of Significant Accounting Policies
Period after the quarter in which prescription is filled for rebate	3 months
Gralise | Minimum
Summary Of Significant Accounting Policies
Product shelf-life	24 months
Gralise | Maximum
Summary Of Significant Accounting Policies
Product shelf-life	36 months
CAMBIA | Minimum
Summary Of Significant Accounting Policies
Product shelf-life	24 months
CAMBIA | Maximum
Summary Of Significant Accounting Policies
Product shelf-life	48 months
Zipsor
Summary Of Significant Accounting Policies
Product shelf-life	36 months
Lazanda | Minimum
Summary Of Significant Accounting Policies
Product shelf-life	24 months
Lazanda | Maximum
Summary Of Significant Accounting Policies
Product shelf-life	36 months
500mg Glumetza
Summary Of Significant Accounting Policies
Product shelf-life	48 months
1000mg Glumetza | Minimum
Summary Of Significant Accounting Policies
Product shelf-life	24 months
1000mg Glumetza | Maximum
Summary Of Significant Accounting Policies
Product shelf-life	36 months
Liability related to sale of future royalties
Summary Of Significant Accounting Policies
Outstanding balance of the liability recognized in Non-cash royalty revenue		42,800,000	147,000,000
Liability related to sale of future royalties | PDL BioPharma
Summary Of Significant Accounting Policies
Royalty and milestone payments received				$ 240,500,000